drugset / Trial / NCT06883552
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm study evaluating the efficacy and safety of Stapokibart Injection in combination with Tislelizumab Injection in patients with driver gene-negative NSCLC who have failed prior PD-1/PD-L1 inhibitor therapy.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | — | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Subcutaneous |
| Subject | Tislelizumab | Monoclonal antibody | 300 mg | Subcutaneous |